RESUMEN
INTRODUCTION: BRCA1/BRCA2 mutation carriers indefinitely comprise a distinct group of patients with breast cancer (BC), with their tumors displaying specific pathologic characteristics. Although these connections are known, they are not fully elucidated. We therefore sought to investigate the clinicopathologic characteristics and overall survival of Greek patients with BC carrying BRCA1/BRCA2 mutations. PATIENTS AND METHODS: Greek patients with BC diagnosed between 1999 and 2016, fulfilling the National Comprehensive Cancer Network criteria for genetic testing, were analyzed for BRCA1/BRCA2 mutations by Sanger sequencing or by a 94-gene panel. Medical records and pathology reports were retrospectively reviewed to retrieve patient and tumor baseline characteristics. Potential associations with mutation status were assessed using the Fisher exact, Pearson χ2, and Mann-Whitney tests. RESULTS: Of 2096 selected patients with BC, we identified 297 (14.2%) BRCA1 and 88 (4.2%) BRCA2 carriers. The mean age at BC diagnosis was 40 and 42.6 years, respectively (P = .02). Tumor histologic subtypes in BRCA1 and BRCA2 carriers were predominantly ductal (79%) followed by medullary (10%), and ductal (72%) followed by lobular (15%), respectively. A significantly higher percentage of BRCA2 tumors were human epidermal growth factor receptor 2-positive, compared with BRCA1 tumors (21.7% vs. 5.8%; P < .001). Second primary cancer diagnosis was more frequent in BRCA1 compared with BRCA2 mutation carriers (36.2% vs. 10.7%; P < .001), whereas there was no difference in 15-year overall survival (hazard ratio, 0.92; 95% confidence interval, 0.48-1.83; P = .804) between the 2 groups. CONCLUSIONS: These data confirm established observations in the pathology of BRCA-related tumors and provide further insight on the association of rare histologic entities with mutations in these genes, which can be clinically beneficial.
Asunto(s)
Neoplasias de la Mama/genética , Mama/patología , Carcinoma Ductal de Mama/genética , Carcinoma Lobular/genética , Carcinoma Medular/genética , Neoplasias Primarias Secundarias/genética , Adulto , Anciano , Proteína BRCA1/genética , Proteína BRCA2/genética , Mama/cirugía , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/patología , Neoplasias de la Mama/terapia , Carcinoma Ductal de Mama/mortalidad , Carcinoma Ductal de Mama/patología , Carcinoma Ductal de Mama/terapia , Carcinoma Lobular/mortalidad , Carcinoma Lobular/patología , Carcinoma Lobular/terapia , Carcinoma Medular/mortalidad , Carcinoma Medular/patología , Carcinoma Medular/terapia , Quimioterapia Adyuvante , Análisis Mutacional de ADN , Femenino , Estudios de Seguimiento , Predisposición Genética a la Enfermedad , Pruebas Genéticas/estadística & datos numéricos , Grecia , Heterocigoto , Humanos , Estimación de Kaplan-Meier , Mastectomía , Persona de Mediana Edad , Mutación , Clasificación del Tumor , Neoplasias Primarias Secundarias/mortalidad , Neoplasias Primarias Secundarias/patología , Neoplasias Primarias Secundarias/terapia , Radioterapia Adyuvante , Estudios Retrospectivos , Resultado del Tratamiento , Adulto JovenRESUMEN
CONTEXT: The evaluation of basal calcitonin (bCT) and stimulated calcitonin (sCT) can be used for the diagnosis and follow-up of medullary thyroid cancer (MTC). OBJECTIVE: The aim of this study was to evaluate the reliability of high-calcium (Ca) test and to identify gender-specific thresholds for MTC diagnosis. PATIENTS: Patients with MTC in remission (n=24) or in persistence (n=18), RET gene mutations carriers (n=14), patients with nodular goiter (n=69), and healthy volunteers (n=16) were submitted to pentagastrin and Ca (25 mg/kg) tests. RESULTS: In all groups, the levels of calcitonin (CT) stimulated by either pentagastrin or Ca were significantly correlated. The prevalence of both C-cell hyperplasia (CCH) and MTC in women and men paralleled the increasing basal and peak CT levels in a gender-specific manner. Receiver operating characteristic plot analyses showed that the best levels of bCT to separate normal and CCH cases from MTC patients were above 18.7 pg/ml in females and above 68 pg/ml in males. Furthermore, Ca sCT above 184 pg/ml in females and above 1620 pg/ml in males had the highest accuracy to distinguish normal and CCH cases from patients with MTC. At the C-cell immunohistochemical examination, Ca sCT below 50 pg/ml corresponded to a mean number of 30 cells per 10 fields, whereas higher sCT associated with a mean number of 400 cells per 10 fields, often displaying a diffuse and nodular distribution pattern. CONCLUSIONS: High-dose Ca test is a potent and well-tolerated procedure that can be applied worldwide at a low cost. Reference ranges for Ca sCT levels in different groups of patients and CT thresholds to diagnose CCH/MTC have been identified.
Asunto(s)
Calcitonina/sangre , Calcio , Carcinoma Medular/diagnóstico , Pentagastrina , Neoplasias de la Tiroides/diagnóstico , Adolescente , Adulto , Anciano , Carcinoma Medular/sangre , Carcinoma Medular/genética , Niño , Preescolar , Femenino , Humanos , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Neoplasias de la Tiroides/sangre , Neoplasias de la Tiroides/genética , Nódulo Tiroideo/sangre , Nódulo Tiroideo/diagnóstico , Nódulo Tiroideo/genéticaAsunto(s)
Bencenosulfonatos/uso terapéutico , Carcinoma Medular/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/uso terapéutico , Piridinas/uso terapéutico , Neoplasias de la Tiroides/tratamiento farmacológico , Administración Oral , Bencenosulfonatos/administración & dosificación , Biomarcadores de Tumor/metabolismo , Calcitonina/metabolismo , Antígeno Carcinoembrionario/metabolismo , Carcinoma Medular/enzimología , Carcinoma Medular/genética , Carcinoma Medular/mortalidad , Carcinoma Medular/secundario , Ensayos Clínicos Fase II como Asunto , Supervivencia sin Enfermedad , Humanos , Escisión del Ganglio Linfático , Metástasis Linfática , Niacinamida/análogos & derivados , Compuestos de Fenilurea , Inhibidores de Proteínas Quinasas/administración & dosificación , Piridinas/administración & dosificación , Sorafenib , Neoplasias de la Tiroides/enzimología , Neoplasias de la Tiroides/genética , Neoplasias de la Tiroides/mortalidad , Neoplasias de la Tiroides/patología , Resultado del TratamientoAsunto(s)
Antineoplásicos/uso terapéutico , Carcinoma Medular/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/uso terapéutico , Neoplasias de la Tiroides/tratamiento farmacológico , Adenocarcinoma Folicular/tratamiento farmacológico , Adenocarcinoma Folicular/genética , Adenocarcinoma Folicular/patología , Antineoplásicos/efectos adversos , Bencenosulfonatos/uso terapéutico , Biomarcadores de Tumor , Carcinoma Medular/genética , Carcinoma Medular/patología , Carcinoma Papilar/tratamiento farmacológico , Carcinoma Papilar/genética , Carcinoma Papilar/patología , Humanos , Indoles/efectos adversos , Indoles/uso terapéutico , Metástasis de la Neoplasia/prevención & control , Niacinamida/análogos & derivados , Compuestos de Fenilurea , Inhibidores de Proteínas Quinasas/efectos adversos , Piridinas/uso terapéutico , Pirroles/efectos adversos , Pirroles/uso terapéutico , Sorafenib , Sunitinib , Neoplasias de la Tiroides/genética , Neoplasias de la Tiroides/patologíaRESUMEN
PURPOSE: Mutations in the RET proto-oncogene and vascular endothelial growth factor receptor (VEGFR) activity are critical in the pathogenesis of medullary thyroid cancer (MTC). Sorafenib, a multikinase inhibitor targeting Ret and VEGFR, showed antitumor activity in preclinical studies of MTC. PATIENTS AND METHODS: In this phase II trial of sorafenib in patients with advanced MTC, the primary end point was objective response. Secondary end points included toxicity assessment and response correlation with tumor markers, functional imaging, and RET mutations. Using a two-stage design, 16 or 25 patients were to be enrolled onto arms A (hereditary) and B (sporadic). Patients received sorafenib 400 mg orally twice daily. RESULTS: Of 16 patients treated in arm B, one achieved partial response (PR; 6.3%; 95% CI, 0.2% to 30.2%), 14 had stable disease (SD; 87.5%; 95% CI, 61.7% to 99.5%), and one was nonevaluable. In a post hoc analysis of 10 arm B patients with progressive disease (PD) before study, one patient had PR of 21+ months, four patients had SD >or= 15 months, four patients had SD Asunto(s)
Bencenosulfonatos/uso terapéutico
, Carcinoma Medular/tratamiento farmacológico
, Inhibidores de Proteínas Quinasas/uso terapéutico
, Piridinas/uso terapéutico
, Neoplasias de la Tiroides/tratamiento farmacológico
, Administración Oral
, Adulto
, Anciano
, Bencenosulfonatos/administración & dosificación
, Bencenosulfonatos/efectos adversos
, Biomarcadores de Tumor/metabolismo
, Carcinoma Medular/enzimología
, Carcinoma Medular/genética
, Carcinoma Medular/mortalidad
, Carcinoma Medular/secundario
, Supervivencia sin Enfermedad
, Femenino
, Humanos
, Estimación de Kaplan-Meier
, Imagen por Resonancia Magnética
, Masculino
, Persona de Mediana Edad
, Mutación
, Niacinamida/análogos & derivados
, Compuestos de Fenilurea
, Tomografía de Emisión de Positrones
, Inhibidores de Proteínas Quinasas/administración & dosificación
, Inhibidores de Proteínas Quinasas/efectos adversos
, Proto-Oncogenes Mas
, Proteínas Proto-Oncogénicas c-ret/antagonistas & inhibidores
, Proteínas Proto-Oncogénicas c-ret/genética
, Piridinas/administración & dosificación
, Piridinas/efectos adversos
, Receptores de Factores de Crecimiento Endotelial Vascular/antagonistas & inhibidores
, Sorafenib
, Neoplasias de la Tiroides/enzimología
, Neoplasias de la Tiroides/genética
, Neoplasias de la Tiroides/mortalidad
, Neoplasias de la Tiroides/patología
, Factores de Tiempo
, Tomografía Computarizada por Rayos X
, Resultado del Tratamiento
, Estados Unidos
, Adulto Joven
RESUMEN
OBJECTIVE: To evaluate the impact of genetic testing in the management of familial multiple endocrine neoplasia 2A patients. DESIGN: Retrospective study. SETTING: University teaching hospital, Hong Kong. PATIENTS: Twenty-two patients from eight multiple endocrine neoplasia 2A families underwent prophylactic total thyroidectomy based on a positive RET mutation genetic testing. All mutations were located at codon 634 of exon 11. Nineteen patients had preoperative basal serum calcitonin measured, and the 12 with normal levels had pentagastrin stimulation tests. Preoperative thyroid ultrasound examination was performed for 17 patients. RESULTS: There were 13 females and 9 males with a median age of 25.1 (range, 6.1-71.9) years. Histopathology revealed medullary thyroid carcinoma in 17 (77%), C-cell hyperplasia in four (18%), and normal pathology in one (5%) of the patients. Five patients with either C-cell hyperplasia or normal pathology were among the youngest (age range, 6-9 years). The youngest patient with medullary thyroid carcinoma was nearly 9 years old. The median size of medullary thyroid carcinomas was 8.3 (range, 0.1-18) mm, but there were no lymph node metastases. Of 15 patients with normal basal calcitonin levels, 10 had medullary thyroid carcinoma, though two tested negative with the pentagastrin-stimulated calcitonin assay. Five of six patients with normal preoperative ultrasonographic examinations had medullary thyroid carcinoma. Three (14%) of the patients were prescribed long-term calcium and vitamin D supplementation. After a median follow-up of 49 (range, 13-128) months, no patient had recurrence of medullary thyroid carcinoma. CONCLUSIONS: Genetic testing has replaced conventional biochemical and radiological modalities to identifying multiple endocrine neoplasia 2A carriers, in order to offer them prophylactic thyroidectomy. Chinese multiple endocrine neoplasia 2A patients with codon 634 mutation seem to have less aggressive forms of medullary thyroid carcinoma, for whom prophylactic thyroidectomy can be considered at the age of 8 years.
Asunto(s)
Pruebas Genéticas , Neoplasia Endocrina Múltiple Tipo 2a/cirugía , Neoplasias de la Tiroides/prevención & control , Tiroidectomía/métodos , Adolescente , Adulto , Anciano , Pueblo Asiatico/genética , Calcitonina/sangre , Compuestos de Calcio/administración & dosificación , Carcinoma Medular/genética , Carcinoma Medular/prevención & control , Carcinoma Medular/cirugía , Niño , China , Femenino , Estudios de Seguimiento , Hospitales Universitarios , Humanos , Masculino , Persona de Mediana Edad , Neoplasia Endocrina Múltiple Tipo 2a/genética , Mutación , Proteínas Proto-Oncogénicas c-ret/genética , Estudios Retrospectivos , Neoplasias de la Tiroides/genética , Neoplasias de la Tiroides/cirugía , Vitamina D/administración & dosificación , Adulto JovenRESUMEN
Thyroid cancer incidence has significantly increased in the last three decades and many patients seek medical attention for its treatment every year. Among follicular cell-derived tumors, the majority are differentiated thyroid carcinomas (DTC), whose prognosis is very good with only 15% of the cases presenting disease persistence or recurrence after initial treatment. Medullary thyroid carcinoma has a worse prognosis, especially in patients with diffused cancers at the time of initial surgery. Traditional treatment options for persistent or recurrent disease include additional surgery, radioiodine treatment and TSH-suppression in DTC patients; external beam radiotherapy, and cytotoxic chemotherapy, often have low efficacy and many patients with advanced disease ultimately die. In the last two decades many of the molecular events involved in cancer formation have been uncovered. This knowledge has prompted the development of novel therapeutic strategies mainly based on the inhibition of key molecular mediators of the tumorigenic process. In particular the class of small-molecule tyrosine kinase inhibitors was enriched by many compounds that have reached clinical trials and in some cases have had approval for clinical use in specific cancers. Many of these compounds entered clinical trials also for locally advanced or metastatic thyroid carcinomas showing very promising results.
Asunto(s)
Antineoplásicos/uso terapéutico , Carcinoma Medular/tratamiento farmacológico , Carcinoma Papilar/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/uso terapéutico , Neoplasias de la Tiroides/tratamiento farmacológico , Axitinib , Bencenosulfonatos/uso terapéutico , Carcinoma Medular/genética , Carcinoma Papilar/genética , Humanos , Imidazoles/uso terapéutico , Indazoles/uso terapéutico , Indoles/uso terapéutico , Niacinamida/análogos & derivados , Niacinamida/uso terapéutico , Oligonucleótidos , Compuestos de Fenilurea , Piperidinas/uso terapéutico , Inhibidores de Proteínas Quinasas/clasificación , Piridinas/uso terapéutico , Pirroles/uso terapéutico , Quinazolinas/uso terapéutico , Sorafenib , Sunitinib , Neoplasias de la Tiroides/genéticaRESUMEN
CONTEXT: In contrast to papillary and follicular thyroid cancer, medullary thyroid cancer (MTC) remains difficult to treat due to its unresponsiveness to radioiodine therapy and its limited responsiveness to chemo- and radiotherapy. OBJECTIVE: To investigate an alternative therapeutic approach, we examined the feasibility of radioiodine therapy of MTC after human sodium iodide symporter (hNIS) gene transfer using the calcitonin promoter to target hNIS gene expression to MTC cells (TT). DESIGN: TT cells were stably transfected with an expression vector, in which hNIS cDNA was coupled to the calcitonin promoter. Functional hNIS expression was confirmed by iodide accumulation assays, Northern and Western blot analysis, immunostaining, and in vitro clonogenic assay. RESULTS: hNIS-transfected TT cells showed perchlorate-sensitive iodide uptake, accumulating 125-I about 12-fold in vitro with organification of 4% of accumulated iodide resulting in a significant decrease in iodide efflux. NIS protein expression was confirmed by Western blot analysis using a monoclonal hNIS-specific antibody, which revealed a major band of a molecular mass of 80-90 kDa. In addition, immunostaining of hNIS-transfected TT cells revealed hNIS-specific immunoreactivity, which was primarily membrane associated. In an in vitro clonogenic assay, 84% of NIS-transfected TT cells were killed by exposure to 131-I, whereas only about 0.6% of control cells were killed. CONCLUSIONS: A therapeutic effect of 131-I has been demonstrated in MTC cells after induction of tissue-specific iodide uptake activity by calcitonin promoter-directed hNIS expression. This study demonstrates the potential of NIS as a therapeutic gene, allowing radioiodine therapy of MTC after tissue-specific NIS gene transfer.
Asunto(s)
Carcinoma Medular/radioterapia , Radioisótopos de Yodo/uso terapéutico , Simportadores/genética , Neoplasias de la Tiroides/radioterapia , Northern Blotting , Western Blotting , Neoplasias de la Mama , Calcitonina/genética , Carcinoma Medular/genética , Línea Celular Tumoral , ADN Complementario , Regulación Neoplásica de la Expresión Génica , Humanos , Inmunohistoquímica , Yoduros/farmacocinética , Regiones Promotoras Genéticas/genética , Neoplasias de la Tiroides/genética , TransfecciónRESUMEN
INTRODUCTION: Medullary thyroid carcinoma (MTC) is a rare thyroid malignancy but accounts for a significant mortality. We present 2 cases of MTC and review the literature regarding its management and genetic screening. CLINICAL PICTURE: Patient 1 presented after a routine health screening and subsequently was found to have a germline mutation for MEN 2A. Patient 2 presented with sweating irritability and a thyroid mass which illustrates the progressive relentless nature of the disease and highlights current imaging practice. TREATMENT: Both patients underwent extensive surgery and received postoperatively ablative dose of radioactive iodine. Patient 2 also had a large dose I-131 MIBG therapy and further surgery. OUTCOME: In Patient 1, postoperative calcitonins remained elevated indicating residual disease. Patient 2 underwent further radioguided surgery; however, his postoperative calcitonins remained elevated. CONCLUSION: MTC can be relentless. Routine genetic screening of all patients with MTC, Tc-99m pentavalent (V) DMSA imaging, near total thyroidectomy with routine central neck dissections and removal of all lymph nodes in the central neck compartment should be performed.